Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma

Autor: Hotte, S. J., Bjarnason, G. A., Heng, D. Y. C., Jewett, M. A. S., Kapoor, A., Kollmannsberger, C., Maroun, J., Mayhew, L. A., scott North, Reaume, M. N., Ruether, J. D., Soulieres, D., Venner, P. M., Winquist, E. W., Wood, L., Yong, J. H. E., Saad, F.
Předmět:
Zdroj: Scopus-Elsevier
Current Oncology
Volume 18
Issue 12
Pages 958-19
Popis: Traditionally, overall survival (os) has been considered the &ldquo
gold standard&rdquo
for evaluating new systemic oncologic therapies, because death is easy to define, is easily compared across disease sites, and is not subject to investigator bias. However, as the available options for continuing therapy increase, the use of os as a clinical trial endpoint has become problematic because of the increasing crossover and contamination of trials. As a result, the approval of promising new therapies may be delayed.
Databáze: OpenAIRE
Externí odkaz: